User profiles for R. S. Gejman
 | Ron S GejmanBrigham and Women's Hospital Verified email at bwh.harvard.edu Cited by 1328 |
[HTML][HTML] Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA …
Background Tumor-infiltrating immune cells have been linked to prognosis and response to
immunotherapy; however, the levels of distinct immune cell subsets and the signals that …
immunotherapy; however, the levels of distinct immune cell subsets and the signals that …
Kinase regulation of human MHC class I molecule expression on cancer cells
…, CY Oh, E Manchado, S Budhu, RS Gejman… - Cancer immunology …, 2016 - AACR
The major histocompatibility complex I (MHC-1) presents antigenic peptides to tumor-specific
CD8 + T cells. The regulation of MHC-I by kinases is largely unstudied, even though many …
CD8 + T cells. The regulation of MHC-I by kinases is largely unstudied, even though many …
Rejection of immunogenic tumor clones is limited by clonal fraction
… While we have not observed alternative cleavage patterns in individual peptides we have
studied (Gejman, 2018b), in a library setting we cannot test if every minigene is properly …
studied (Gejman, 2018b), in a library setting we cannot test if every minigene is properly …
[HTML][HTML] A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is
expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to …
expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to …
Opportunities and challenges for TCR mimic antibodies in cancer therapy
Introduction: Monoclonal antibodies (mAbs) are potent cancer therapeutic agents, but
exclusively recognize cell-surface targets whereas most cancer-associated proteins are found …
exclusively recognize cell-surface targets whereas most cancer-associated proteins are found …
T cell receptor mimic antibodies for cancer therapy
The major hurdle to the creation of cancer-specific monoclonal antibodies (mAb) exhibiting
limited cross-reactivity with healthy human cells is the paucity of known tumor-specific or …
limited cross-reactivity with healthy human cells is the paucity of known tumor-specific or …
Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform
… RS Gejman has ownership interest in the patent filed on the PresentER technology (US
provisional patent application no. 62/395,577). AY Chang is a postdoctoral research fellow at …
provisional patent application no. 62/395,577). AY Chang is a postdoctoral research fellow at …
Cytokine response over the course of COVID-19 infection in pregnant women
DB Rosen, EA Murphy, RS Gejman, A Capili… - Cytokine, 2022 - Elsevier
… Daniel B Rosen and Ron S Gejman were funded by a Medical Scientist Training Program
grant from the National Institute of General Medical Sciences of the NIH (T32GM007739) to the …
grant from the National Institute of General Medical Sciences of the NIH (T32GM007739) to the …
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment
Exploring the repertoire of peptides presented on major histocompatibility complexes (MHCs)
helps identify targets for immunotherapy in many hematologic malignancies. However, …
helps identify targets for immunotherapy in many hematologic malignancies. However, …
The landscape of T cell infiltration in human cancer and its association with antigen presenting gene expression
One sentence summary In silico decomposition of the immune microenvironment among
common tumor types identified clear cell renal cell carcinoma as the most highly infiltrated by T-…
common tumor types identified clear cell renal cell carcinoma as the most highly infiltrated by T-…